Ieq Capital LLC Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Ieq Capital LLC increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 557,904 shares of the company's stock after purchasing an additional 45,424 shares during the quarter. Neurocrine Biosciences makes up about 0.7% of Ieq Capital LLC's holdings, making the stock its 23rd biggest position. Ieq Capital LLC owned approximately 0.55% of Neurocrine Biosciences worth $76,154,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Golden State Wealth Management LLC bought a new stake in Neurocrine Biosciences in the fourth quarter worth about $25,000. Brooklyn Investment Group raised its position in shares of Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after purchasing an additional 115 shares during the period. Blue Trust Inc. boosted its holdings in Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company's stock worth $40,000 after buying an additional 220 shares during the period. R Squared Ltd purchased a new position in Neurocrine Biosciences in the 4th quarter valued at approximately $61,000. Finally, UMB Bank n.a. raised its holdings in Neurocrine Biosciences by 211.6% during the 4th quarter. UMB Bank n.a. now owns 455 shares of the company's stock valued at $62,000 after acquiring an additional 309 shares during the period. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock traded up $4.20 during trading hours on Friday, reaching $120.31. The company had a trading volume of 1,234,742 shares, compared to its average volume of 1,316,890. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The company has a 50-day moving average price of $136.75 and a 200 day moving average price of $129.71. The firm has a market cap of $11.99 billion, a price-to-earnings ratio of 36.56, a P/E/G ratio of 0.76 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. As a group, research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 65,000 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00. Following the transaction, the chief executive officer now owns 135,392 shares in the company, valued at approximately $19,157,968. This represents a 32.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kevin Charles Gorman sold 5,844 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total transaction of $681,936.36. Following the sale, the director now directly owns 521,618 shares of the company's stock, valued at $60,867,604.42. This trade represents a 1.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 236,600 shares of company stock valued at $34,348,261. Corporate insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NBIX. Wedbush reduced their target price on Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Guggenheim reduced their target price on Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating for the company in a research report on Monday, February 10th. Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Neurocrine Biosciences in a research report on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price objective on the stock. Finally, Morgan Stanley lifted their target price on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $166.90.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.